atc sales, page-5

worthind's last post, discussed Bristol-Myers Squibb perspective insofar as a possible acquistion/partnership with Avexa.

Nice work, as always: I hope your sending this stuff to Nathan Drona and the Avexa board, err, unlees of course you are Nathan Drona (just kidding).

I admit to feeling relaxed and comfortable about the next 6 months - always a dangerous feeling to have, but at least there's not so long to wait before crunch time. Either the Phase-III trails are good enough to prove ATC is marketable (in which case I'm sure the market will find a way to market it), or ATC falls at the last hurdle - always a possibility.

Worthind - what's your take in the value of Avexa without ATC?
Cheers,